Faron Pharmaceuticals: Initiating phase II part of BEXMAB study - Redeye

Redeye provides a comment following Faron’s announcement of the initiation of the phase II part of the ongoing BEXMAB study. We believe that the promising interim analyses from the initial part of the study warrants further development of bexmarilimab in hematological malignancies and are encouraged to learn that the second part is now underway.

Länk till analysen i sin helhet: https://www.redeye.se/research/955876/faron-pharmaceuticals-initiating-phase-ii-part-of-bexmab-study?utm_source=finwire&utm_medium=RSS